China Biologic Products Holdings Inc
China Biologic Products — Investor Presentation (September 2008)
29 slides from China Biologic Products's investor presentation, Sep 9, 2008
Slide 1: China Biologic Products, Inc.
September 2008 5 e, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China
Slide 2: Safe Harbor Statement
@ Safe Harbor Statement CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation includes or incorporates by reference statements that constitute forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securit
Slide 3: Equity Snapshot
@.@ ~~ Equity Snapshot Ticker CBPO.OB Market Capitalization: $68 M Revenues (ttm): $35.7M Net Income’ (ttm): $8.4M Wtd Avg Diluted Shares as of 06/30/08 22M Diluted Earnings Per Share* (ttm) $0.38 PIE* (ttm) 2X “Excludes non cash stock based compensation expenses. », China Biologic Products, Inc. 3
Slide 4: Company Overview
. @ Company Overview Our Mission: To be the leading provider " A 5 36,000 Revenues of plasma- based biopharmaceutical on (US$ in Thousands) products in China 26,000 22231 20,000 Only approved manufacturer of plasma- 16,000 11,869 based biopharmaceutical products in doco ates Shandong, China, the sec
Slide 5: Investment Highlights
Investment Highlights « Rising demand for plasma-based products « Stringent regulatory requirements, consolidating market creates tight supply conditions « China Biologic has secured limited raw materials supply « Growing portfolio of high-margin products « Regional expansion opportunities « Solidly
Slide 6: China Biologic's Products are Essential to Health Care
—————— China Biologic’s Products are Essential to Health Care Human Albumin plasma protein formed in the liver and accounts for about 60% of protein in blood. Applications include emergency blood loss, burns, volume replacement during and after surgery, improvement of wound healing, albumin-depletin
Slide 7: One of Top Pharmaceutical Products Purchased by Hospitals in China
One of Top 10 Pharmaceutical Products Purchased by Hospitals in China Product RMB million USS milli Toubaopaitongna Cefoperazone Sx 2,732 339 Levofloxacin 2,321 288 Ceftazidime 1,620 201 Azithromycin 1,471 182 Thymosin. 1,284 159 Sodium Chloride 1,260 156 Note: The current market size of Human Album
Slide 8: Plasma Market: China vs. Developed Nations
Plasma Market: China vs. Developed Nations More developed PRC usage as a % of PRC countries more developed (Per million population) (Per million population) countries Albumin 100kq 200-300kg 33.3%-50% IMGG (Intravenous Immunoglobulin G) tkg 10kg 10% Factor VIII 0.1 1U 11U 10% Range of Plasma Product
Slide 9: Revenue Breakdown
@ @Revenue Breakdown Product Sales Mix and Product Growth Rates % of 142007 | % of 1H2008 | Volume PRODUCT Sales Sales Growth Rate Ta Revenue Breakdown Albumin ace for 1% Half of 2008 4.4% 8.0% 120.0% Human Immunoglobulin 5 5 forint avondale 46% 18.8% 387.2% 14.6% 8.3% -32.0% Human Tetanus : 5 Taene
Slide 10: Industry Overview
fidustry Overview Plasma-based products are critical treatments to life-threatening diseases Highly regulated by the government due to the nature of risks involved in human plasma based products Regulation on plasma supply and final product approval process creates shortage of plasma- based products
Slide 11: Mandates Strengthen Market Structure/Drive Consolidation
andates Strengthen Market ture/Drive Consolidation wet Stringent Regulation by Government J Produces Improved Quality of Collection Stations and Final Plasma Products Creates Favorable Market —+ Conditions + Mandatory reform of blood collection stations in 2006 + Heightened safety and hygienic stand
Slide 12: Plasma Collection
@.®@ Plasma Collection — 2005 2007 Total Collected Volume of Plasma in China is Declining Rapidly 2700 (Tons) 5000 (Tons) Collected Plasma in China Collected Except Plasma in CBPO China 97.0% Except CBPO 90.4% Collected Plasma by eee an CBPO ae 9.6% CBPO sourcing from plasma stations: 3 CBPO plasma
Slide 13: China Biologic's GMP certification was renewed in August 2008
« China Biologic’s GMP certification was renewed in August 2008 i « GMP certification is granted by the SFDA and assures the quality, safety, and effectiveness of pharmaceutical products « High barrier to entry: GMP certification is no longer granted to new manufacturers beginning in 1999 « Stricter
Slide 14: Stringent Quality Control
. . . . . . . . @ Gtringent Quality Control One of the first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 Awarded Advanced High-tech Enterprise Certification by the Department of Science and Technology of Shandong Province (2005) Awarded Advanced High-tech
Slide 15: Secure the supply of plasma
« Secure the supply of plasma + Relocate plasma collection station to increase collection volume + Capacity expansion and Increase pS eee utilization at newly expanded } production facility + Build new collection stations « Acquire competitors or other biologic related companies « Further strengthen
Slide 16: Securing the Plasma Supply
Securing the Plasma Supply Securing the plasma supply « December 2006 — Acquired the assets of five of the six plasma collection stations in Shandong Province Provides over 200 tons of plasma supply, while total plasma collected in China is less than 3,000 tons per year « February and April 2007 — A
Slide 17: Focus on R&D
Focus on R&D On-going R&D Objectives « Broaden the breadth and depth of our portfolio of plasma-based biopharmaceutical products « Enhance the yield per unit volume of plasma through new collection techniques «+ Maximize manufacturing efficiency and safety + Promote product safety through implementa
Slide 18: New Product Pipeline
@New Product Pipeline Cryoprecipitate (raw material for Production approved for sales by the SFDA in 2008 Human Coagulation Factor VIII) Human Albumin(12.5g/vial) Production approved for sales by the SFDA in 2008 Human Hepatitis BImmunoglobulin Approved to commence clinical trial (stage 8) (pH 4) fo
Slide 19: Increase Customer Penetration and Expand into Other Provinces
Increase Customer Penetration and Expand into Other Provinces « Increase penetration at existing customers with new products « Expand geographic reach + Shandong Province accounts for 42% of total revenue for 2007 + Continue marketing efforts in Jiangsu, Zhejiang, Henan and northeastern part of Chin
Slide 20: Management team
Chao Ming Zhao, CEO + Chief Financial Officer of China operating subsidiary between September 2003 and May 2008 + Over 10 years of experience in finance, accounting and internal control + Certified Accountant in the PRC and an international registered internal auditor + MBA in finance from Chinese U
Slide 21: Financial Highlights
®* China Biologic Products Financial Highlights ¢ & China Biologic Products, Inc. 21
Slide 22: Growing Revenues
35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 @ Growing Revenues (USS in Thousands) 32,399 o ” 22,234 a. 774 16,503, 11,559 8,163 2004 2005 2006 2007 4H2007 1H 2008 ¢ China Biologic Products, Inc. 22
Slide 23: Rising Net Income
Rising Net Income (USS in Thousands) 9,000 8,000 7,000 fe) 6,000 5,342 5,565 5,000 Wat 3,817 3,000 2,000 1,310 4,000 515 Hl 0 i! 2004 2005 2006 2007 1H 2007 1H 2008" EPS-Diluted $0.37 $0.25 $0.26 *Exeludes $1.26M in Stock Based Compensation C China Biologic Products, Inc. 23
Slide 24: Income Statement
@ @ Income Statement Consolidated Income Statement Six Months Ended June 30 Year Ended Dec 34 {$ in millions) 4H 2008 4H 2007 -2007 2006 Gross Profit 14.2 10.5 22.5 12.6 Operating income 8.6 78 12.8 6.2 Operating Margin 43.5% 39.5% Net income* 5.6 5.3 8.2 3.8 Net Margin* 28.1% 32.4% 25.2% 17.2% Wtd
Slide 25: Balance Sheet
[email protected] Balance Sheet Consolidated Balance Sheets December 34 June 30. ($ in Millions) 2006 2007 2008 Cash $4.3 $5.0 $8.8 Inventory $6.1 $9.5 $12.8 Total Current Assets $15.5 $15.7 $23.9 Total Assets $24.5 $33.3 $44.3 Total Current Liabilities $8.8 $6.9 $9.6 Total Stockholder's Equity $12.7 $22.4 $29.8
Slide 26: Peer valuation comparison
Revenue Tr 9 Forward Seles PIE PIE (08E) Stock Price 2007 (8/29/08) Revenues Hualan Biological Engineering Inc. Beijing Tiantan Biological Products 600161.ss $1.44 $69.9m 27.3% $0.04 83.8 40.0 Corp. Ltd. Unisplendour Guhan Group Shanghai RAAS Blood Products Co., 002252.ss. $3.26 $44.3m 11.2% $0.10 4
Slide 27: Investment summary
Rapidly growing demand for plasma- based products Under penetrated, consolidating market Securing raw materials supply High barriers to entry with strict regulatory environment Growing portfolio of high- margin products Geographic expansion opportunities Attractive valuation vs. peers & China Biolog
Slide 28: China Biologic Products Inc. and CCG Investor Relations contacts
China Biologic Products Inc. CCG Investor Relations Inc. Y. Tristan Kuo Crocker Coulson, President No.14 East Hushan Road 1325 Avenue of the Americas, Suite 2800 Taian City, Shandong 271000 New York, NY 10019 PRC Tel: 1 (646) 213-1915 Tel: 86 538-6202306 [email protected] [email protected]
Slide 29: Adjusted Net Income
Adjusted Net Income Year Ended December 31, 2007 Year Ended December 31, 2006 Net Income (Loss) Diluted El Net Income Diluted El Net Income Diluted EPS Adjusted Amount - Non GAAP. $8,179,376 $0.37 $3,816,837 $0.18 Non-cash employee compensation = = . = Amount per consolidated statement of operations
China Biologic Products — Investor Presentation (September 2008) on 6ix